PSC
CLDX icon

Prentiss Smith & Co’s Celldex Therapeutics CLDX Stock Holding History

Prentiss Smith & Co’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-7
Closed -$1K – 349
2015
Q3 		$1K Hold
7
– – ﹤0.01% 317
2015
Q2 		$3K Hold
7
– – ﹤0.01% 263
2015
Q1 		$3K Hold
7
– – ﹤0.01% 283
2014
Q4 		$2K Hold
7
– – ﹤0.01% 299
2014
Q3 		$1K Hold
7
– – ﹤0.01% 235
2014
Q2 		$2K Hold
7
– – ﹤0.01% 228
2014
Q1 		$2K Hold
7
– – ﹤0.01% 239
2013
Q4 		$2K Hold
7
– – ﹤0.01% 235
2013
Q3 		$4K Hold
7
– – ﹤0.01% 211
2013
Q2 		$2K Buy
+7
New +$1.38K ﹤0.01% 242

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Prentiss Smith & Co's CLDX Position: Q4 2015 in Review

Prentiss Smith & Co sold out of Celldex Therapeutics (CLDX) in Q4 2015, closing a stake of 7 shares — an estimated $1K sold.

Prentiss Smith & Co first reported a position in CLDX in Q2 2013 and held it in 10 quarters. The position peaked at $4K in Q3 2013. 171 funds tracked by Wall St. Rank hold CLDX as of Q4 2015.

  • Prentiss Smith & Co reported no remaining Celldex Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Prentiss Smith & Co sold 7 Celldex Therapeutics shares in Q4 2015, an estimated $1K.
  • Prentiss Smith & Co first reported a position in Celldex Therapeutics in Q2 2013 and held it in 10 quarters.
  • Prentiss Smith & Co's Celldex Therapeutics position peaked at $4K in Q3 2013.
  • 171 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2015.

Based on Prentiss Smith & Co's 13F filing for Q4 2015, filed 21 Jan 2016.